Running immunoassays at nanoliter-scale reduces sample requirements and reagent consumption by up to a hundredfold.
The individual microstructures of Gyrolab CDs ensure precise volume definition which eliminates pipetting errors and the risk of cross-talk. Samples are processed under uniform conditions to maximize reproducibility and reliability.
Using Gyrolab Bioaffy CDs, you can easily develop robust nanoliter-scale immunoassays exhibiting broad dynamic ranges. The CDs minimize reagent and sample consumption and deliver highly reproducible results in less than an hour. Our CDs offer full flexibility in assay design to quantify any protein, providing you have a suitable binding pair (biotinylated capture and Alexa Fluor® detection reagents).
Select the appropriate CD for a specific assay based on the required dynamic range, the analyte concentration, the quality of reagents and the assay format. With a sample volume of 200 nL, Gyrolab Bioaffy 200 CD is the starting point for the majority of applications. Increased sensitivity, for example in biomarker and HCP assays, can be achieved with the Bioaffy 1000 while Bioaffy 20 HC is suitable for applications where high analyte concentrations need to be measured, such as when determining IgG titer in cell line development.
Assays can easily be transferred between the different CD types to accommodate wide ranges of analyte concentrations.
Gyrolab Mixing CD 96 integrates and automates sample pretreatment into the assay workflow made possible by Gyrolab platforms. Automating sample pretreatment and immunoassay workflow at nanoliter scale creates a number of advantages including:
In Gyrolab automated method for detection of leached MabSelect SuRe™ ligands and native Protein A , samples are acidified in Gyrolab Mixing CD 96 to dissociate protein A-IgG complexes. The amount of Protein A is then determined by a sandwich immunoassay.
For anti-drug antibody (ADA) analysis in preclinical or clinical serum samples, the mixing function in the Gyrolab Mixing CD 96 can be used to automate sample pre-treatment for acid dissociation of interfering biotherapeutic. Miniaturization simplifies detection of anti-drug antibodies, even in the presence of a high drug concentration. The individual microstructures integrate the acid dissociation process to minimize variation between samples, while edicated Gyrolab ADA software supports assay development and validation for cut point determination, screening and confirmatory analysis.
when used for ADA analysis.
Contact Gyros Protein Technologies for assistance with your assay development needs.